Results 141 to 150 of about 22,643,381 (355)
Romanian Journal of Laboratory MedicineThis study presents a transversal investigation that we performed at Fundeni hospital (Bucharest, Romania) into the therapeutic benefits and efficacy of Emicizumab, a non-factor therapy, in the context of hemophilia A.
Brinza Melen +5 more
doaj +1 more source
Therapeutics and Clinical Risk Management, 2020 Silvia Linari, Giancarlo Castaman Department of Oncology, Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, ItalyCorrespondence: Giancarlo CastamanDepartment of Oncology, Center for Bleeding Disorders and Coagulation ...
Linari S, Castaman G
doaj
Desmopressin in moderate hemophilia A patients: a treatment worth considering
Haematologica, 2018 Desmopressin increases endogenous factor VIII levels in hemophilia A. Large inter-individual variation in the response to desmopressin is observed.
J. I. Loomans +11 more
semanticscholar +1 more source
Pediatric InvestigationImportance Emicizumab (EMI) is efficacious and safe for hemophilia A (HA) prophylaxis. However, its high cost poses a challenge in China. Objective To explore the possibility of using reduced‐dosage EMI in Chinese HA children.
Qianqian Mao +12 more
doaj +1 more source
THE CONDITION OF THE BLOOD IN HEMOPHILIA, THROMBOSIS AND PURPURA [PDF]
, 1914 W. H. Howell
openalex +1 more source
Haemophilia Prophylaxis in the Age of Innovation: Exploring Opportunities for Personalized Treatment
Haemophilia, EarlyView.ABSTRACT Introduction Recent advancements in haemophilia treatment have introduced a range of innovative therapies, including activated FVIII mimetics, ultra‐extended half‐life recombinant FVIII, rebalancing agents and gene therapy. These developments have transformed treatment options and expanded prophylaxis strategies.
Yesim Dargaud +5 more
wiley +1 more source
Combined Hemophilia and PTC Deficiency [PDF]
, 1955 Joseph M. Hill, R. J. Speer
openalex +1 more source
Haemophilia, EarlyView.ABSTRACT Introduction Heavy menstrual bleeding (HMB) is a common presenting symptom in women with bleeding disorders, yet haemostatic testing is sometimes overlooked, even when refractory HMB requires surgical intervention. Aim To determine the prevalence of bleeding disorders in women referred for surgical management of HMB and investigate screening ...
Alison Delaney +8 more
wiley +1 more source
Hematology, 2006 Acquired hemophilia A is a rare but severe autoimmune bleeding disorder, resulting from the presence of autoantibodies directed against clotting factor VIII. The etiology of the disorder remains obscure, although approximately half of all cases are associated with other underlying conditions.
openaire +3 more sources
Molecular Therapy: Nucleic Acids, 2023 Gene therapy and rebalancing therapy have emerged as promising approaches for treating hemophilia A, but there are limitations, such as temporary efficacy due to individual differences.
Jeong Pil Han +10 more
doaj